BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3937785)

  • 1. Anticytoskeleton autoantibodies and chronic graft versus host disease.
    Gobbi M; Tazzari P; Tassinari A; Bandini G; Zauli D; Crespi C; Miserocchi F; Tura S
    Haematologica; 1985; 70(5):457-8. PubMed ID: 3937785
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets.
    Przepiorka D; Huh YO; Khouri I; Reading C; Hester J; Marshall M; Champlin RE
    Prog Clin Biol Res; 1994; 389():557-63. PubMed ID: 7700921
    [No Abstract]   [Full Text] [Related]  

  • 4. Sonography of the gallbladder in bone marrow transplant patients.
    Frick MP; Snover DC; Feinberg SB; Salomonowitz E; Crass JR; Ramsay NK
    Am J Gastroenterol; 1984 Feb; 79(2):122-7. PubMed ID: 6364795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bases of bone marrow transplantation: modalities and indications].
    García Laraña J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():14-21. PubMed ID: 10422446
    [No Abstract]   [Full Text] [Related]  

  • 6. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-mitosin antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Muro Y; Kamimoto T; Hagiwara M
    Bone Marrow Transplant; 1997 May; 19(9):951-3. PubMed ID: 9156273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Altered immunity syndrome", a distinct entity in long-term bone marrow transplantation survivors?
    Trendelenburg M; Gregor M; Passweg J; Tichelli A; Tyndall A; Gratwohl A
    Bone Marrow Transplant; 2001 Dec; 28(12):1175-6. PubMed ID: 11803364
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute graft-versus-host disease in allogeneic bone marrow transplantation].
    Harada M; Funada H; Yoshida T; Kodo H; Mori T; Matsue K; Shiobara S; Ohtake S; Odaka K; Teshima H
    Rinsho Ketsueki; 1984 Jul; 25(7):1043-51. PubMed ID: 6389930
    [No Abstract]   [Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive donor-to-recipient transfer of antiphospholipid syndrome following allogeneic stem-cell transplantation.
    Ritchie DS; Sainani A; D'Souza A; Grigg AP
    Am J Hematol; 2005 Aug; 79(4):299-302. PubMed ID: 16044450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.